Motivation: Biomarker discovery is one of the most frequent pursuits in bioinformatics and is crucial for precision medicine, disease prognosis, and drug discovery. A common challenge of biomarker discovery applications is the low ratio of samples over features for the selection of a reliable not-redundant subset of features, but despite the development of efficient tree-based classification methods, such as the extreme gradient boosting (XGBoost), this limitation is still relevant. Moreover, existing approaches for optimizing XGBoost do not deal effectively with the class imbalance nature of the biomarker discovery problems, and the presence of multiple conflicting objectives, since they focus on the training of a single-objective model. In the current work, we introduce MEvA-X, a novel hybrid ensemble for feature selection (FS) and classification, combining a niche-based multiobjective evolutionary algorithm (EA) with the XGBoost classifier. MEvA-X deploys a multiobjective EA to optimize the hyperparameters of the classifier and perform FS, identifying a set of Pareto-optimal solutions and optimizing multiple objectives, including classification and model simplicity metrics.

Results: The performance of the MEvA-X tool was benchmarked using one omics dataset coming from a microarray gene expression experiment, and one clinical questionnaire-based dataset combined with demographic information. MEvA-X tool outperformed the state-of-the-art methods in the balanced categorization of classes, creating multiple low-complexity models and identifying important nonredundant biomarkers. The best-performing run of MEvA-X for the prediction of weight loss using gene expression data yields a small set of blood circulatory markers which are sufficient for this precision nutrition application but need further validation.

Availability And Implementation: https://github.com/PanKonstantinos/MEvA-X.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354005PMC
http://dx.doi.org/10.1093/bioinformatics/btad384DOI Listing

Publication Analysis

Top Keywords

biomarker discovery
12
multiobjective evolutionary
8
xgboost classifier
8
meva-x tool
8
gene expression
8
meva-x
6
discovery
5
meva-x hybrid
4
hybrid multiobjective
4
evolutionary tool
4

Similar Publications

Update on the Progress of Musashi-2 in Malignant Tumors.

Front Biosci (Landmark Ed)

January 2025

Department of Hepatobiliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 030032 Taiyuan, Shanxi, China.

Since the discovery of the Musashi (MSI) protein, its ability to affect the mitosis of Drosophila progenitor cells has garnered significant interest among scientists. In the following 20 years, it has lived up to expectations. A substantial body of evidence has demonstrated that it is closely related to the development, metastasis, migration, and drug resistance of malignant tumors.

View Article and Find Full Text PDF

The deposition of monosodium urate (MSU) crystals within joint spaces produces a painful inflammatory condition known as gout, a specific form of arthritis. The condition calls for a combined curative and preventive management model. A new development in the approach to gout is that of NLRP3-targeted biologic agents, such as monoclonal therapies, to provide more accurate treatment by blocking specific pro-inflammatory cytokines.

View Article and Find Full Text PDF

Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies.

Pharmaceuticals (Basel)

January 2025

Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, 0317 Oslo, Norway.

Cytokine-mediated inflammation is increasingly recognized for playing a vital role in the pathophysiology of a wide range of brain disorders, including neurodegenerative, psychiatric, and neurodevelopmental problems. Pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) cause neuroinflammation, alter brain function, and accelerate disease development. Despite progress in understanding these pathways, effective medicines targeting brain inflammation are still limited.

View Article and Find Full Text PDF

Discovery of Novel Diagnostic Biomarkers for Common Pathogenic Through Pan-Genome and Comparative Genome Analysis, with Preliminary Validation.

Pathogens

January 2025

Department of Clinical Laboratory, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Institute, Capital Medical University, Beijing 101100, China.

The aim of this study was to reveal diagnostic biomarkers of considerable importance for common pathogenic , utilizing pan-genomic and comparative genome analysis to accurately characterize clinical infections. In this study, complete or assembled genome sequences of common pathogenic and closely related species were obtained from NCBI as discovery and validation sets, respectively. Genome annotation was performed using Prokka software, and pan-genomic analysis and extraction of core genes were performed using BPGA software.

View Article and Find Full Text PDF

Improving Replication in Endometrial Omics: Understanding the Influence of the Menstrual Cycle.

Int J Mol Sci

January 2025

Department of Obstetrics and Gynaecology, University of Melbourne, and Gynaecology Research Centre, Royal Women's Hospital, Parkville, VIC 3052, Australia.

The dynamic nature of human endometrial tissue presents unique challenges in analysis. Despite extensive research into endometrial disorders such as endometriosis and infertility, recent systematic reviews have highlighted concerning issues with the reproducibility of omics studies attempting to identify biomarkers. This review examines factors contributing to poor reproducibility in endometrial omics research.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!